Testing how ketones may affect heart benefits in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You have heart failure with reduced pumping (NYHA Class II–III, ejection fraction under 50%)
- You are 18 to 80 years old and your body mass index (BMI) is 23 to 38
- Your recent blood sugar measure (HbA1c) is between 5.5% and 10% and your blood pressure is at or below 145/85
- Your kidney function is enough for the study (eGFR at least 30) and your heart/diabetes medicines and weight are stable
- You can safely get an MRI (no pacemaker or metal fragments) and you don’t have severe claustrophobia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests whether taking a special oral ketone supplement can help people with both heart failure and diabetes. It looks at both short-term and long-term effects on heart function and blood sugar control.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
Hear when a new Type2 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.